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Background: The care given to moderate and severe traumatic brain injury (TBI) patients may be 
hampered by the inability to tailor their treatments according to their neurological status. Contrast-enhanced 
near-infrared spectroscopy (NIRS) with indocyanine green (ICG) could be a suitable neuromonitoring tool. 
Methods: Monitoring the effective attenuation coefficients (EAC), we compared the ICG kinetics between 
five TBI and five extracranial trauma patients, following a venous-injection of 5 mL of 1 mg/mL ICG, using 
two commercially available NIRS devices. 
Results: A significantly slower passage of the dye through the brain of the TBI group was observed in 
two parameters related to the first ICG inflow into the brain (P=0.04; P=0.01). This is likely related to 
the reduction of cerebral perfusion following TBI. Significant changes in ICG optical properties minutes 
after injection (P=0.04) were registered. The acquisition of valid optical data in a clinical environment was 
challenging. 
Conclusions: Future research should analyze abnormalities in the ICG kinetic following brain trauma, 
test how these values can enhance care in TBI, and adapt the current optical devices to clinical settings. Also, 
studies on the pattern in changes of ICG optical properties after venous injection can improve the accuracy 
of the values detected.
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Introduction
Over the last decade, the burden of global neurotrauma 
has been on the rise (1). The efficacy of the care given to 
these patients has been called into question: a randomized 
clinical trial to test hypothermia therapy was terminated 
early due to its poor outcomes (2); Cooper et al. reported 
that performing early decompressive craniectomies for the 
treatment of intracranial hypertension did not enhance 
patient outcomes (3), while Hutchinson et al. reported 
a lower mortality rate in patients who undertook ‘last 
resort’ decompressive craniectomies, but only modest 
improvement to outcomes (4). One of the main differences 
between the studies from Cooper et al. and the one 
from Hutchinson et al. is that, while in the former the 
decompressive craniectomy was performed as one of the 
first therapeutic interventions, in the latter it was one of the 
last, made following other unsuccessful interventions. This 
may lead one to think that only a portion of those who had 
been under surgery in the study of Cooper et al. would have 
found the decompressive craniectomy beneficial, while the 
others could have received a more conservative treatment.
Chesnut et al. suggested that the lack of subtype-
classification in recruited TBI patients may be responsible 
for the limited improvements observed (5). This is linked 
fundamentally to limitations in injury burden stratification 
with current multimodal neuromonitoring tools (6): 
computed tomography (CT), for example, limits analysis to 
anatomical pathology without giving a clear picture of the 
complexity of post-injury pathophysiology (particularly at 
the bedside) including neuronal injury, perfusion deficiency, 
metabolic crisis, etc. (7,8). The intracranial pressure (ICP) 
has fundamental limitations in that it is only a surrogate for 
cerebral perfusion, calculated via the differential between 
the pressure in the systemic vasculature and in the head. 
The ICP monitor limits analysis to the brain area in which 
it is inserted and cannot record different effects of trauma 
across the hemispheres (9). This motivates the adoption 
of detectable biomarkers in clinical neurotrauma, and 
the importance of coupling them to radiological patterns 
including magnetic resonance imaging (MRI), or other 
objective biological measurements into more robust and 
reliable biosignatures (10).
Cerebral perfusion and the integrity of the blood-brain 
barrier (BBB) can be impaired after brain trauma (11,12). 
The analysis of these two parameters, either focally or 
globally, could comprise a more in-depth assessment of 
a patient’s status and provide an alternative method for 
stratifying their severity. This can lead to:
(I) Development of novel treatments to reverse the 
directly observed pathology;
(II) Better direction of existing therapy towards 
individuals most likely to experience benefit.
Near-infrared spectroscopy (NIRS) can be a useful non-
invasive, continuous, bedside neuromonitoring tool in the 
care of TBI patients (13). Studies on humans and animals 
have measured cerebral perfusion and vascular permeability 
after brain trauma by monitoring the kinetics of a contrast 
dye, indocyanine green (ICG), with NIRS devices (14-17). 
Unlike NIRS, other dynamic contrast-enhanced imaging 
techniques (i.e., CT, MRI) expose patients to ionizing 
radiation and/or cannot be performed continuously at the 
patients’ bedsides (18). Currently, the ICG cerebral vascular 
kinetics monitored through contrast-enhanced NIRS in 
TBI patients remains to be fully investigated clinically.
ICG is a contrast dye with absorption and fluorescence 
properties in the NIR spectral range, and is commonly 
used in clinical practice (e.g., neuro-oncology; theranostic 
nanomedicine) (19-22). The ICG photon absorption is 
related to the dye concentration and to the nature of the 
solvent in which it is dissolved (23). In water, an increase 
in dye concentration drives changes in its absorption 
coefficient due to the progressive formation of ICG 
aggregates, which have an absorption peak at 690 nm 
wavelength, starting from the ICG monomers, which 
have a peak at 785 nm (19,23,24). In blood, ICG is bound 
by a large spectrum of proteins and lipids (19,25). This 
binding process shifts the absorption peak to approximately 
810 nm within a few seconds and stabilizes the dye’s optical 
properties by interfering with the formation of ICG 
aggregates (19,23,26).
Herein, we monitored the ICG kinetics in the brains 
of TBI and extracranial trauma (non-TBI) patients by 
measuring the effective attenuation coefficient (EAC) at 
multiple wavelengths, using two commercially available 
depth-resolved continuous-wave (CW) and frequency-
domain (FD)-NIRS devices (27-30). During the first ICG 
passage into the cerebral circulation, we hypothesized that 
we would observe an ICG optical signal for a longer period 
of time in the TBI group than in the non-TBI group, due to 
more impaired and attenuated brain perfusion in the former 
than in the latter. We also anticipated a prolonged ICG 
signal in the TBI group within a few minutes post-injection, 
due to leakage of the dye into the interstitial tissue of the 
parenchyma as a result of increased BBB permeability.
Furthermore, we compared the ICG absorption 
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properties at different wavelengths after injection by 
analyzing the slow changes in the EAC. We hypothesized 
that the highest level of photon absorption by the ICG 
would be at around 810 nm, and no significant changes 
to ICG optical properties would be observed after a few 
seconds from the injections.
Methods
Equipment
A three wavelengths (735 nm, 810 nm, 850 nm) CW-NIRS 
device, NIRO-200NX (Hamamatsu Photonics, Tokyo, 
Japan), and a two-wavelengths (690 nm, 830 nm) FD-NIRS 
device, ISS-OxiplexTSTM (ISS Inc., Champaign, Illinois, 
USA) were used.
Both these devices employ a spatial ly resolved 
spectroscopy (SRS) NIRS approach with multiple source-
detector distances (31,32). The SRS approach permits 
enhanced sensitivity to deep (few cm) structures and 
inference of the EAC, which is related to the exponential 
decay of the light signal with distance (27).
Participants
Five moderate and severe TBI (three males; mean age: 58) 
and five non-TBI patients (three males; mean age: 59), 
admitted to the ward or the intensive therapy unit (ITU) 
of the Queen Elizabeth Hospital Birmingham (UK) were 
enrolled into the study. Participants with suspected liver or 
kidney dysfunction were excluded from the study.
Four TBI patients were tested less than 14 days from 
injury (mean days: 8) while under sedation and one TBI 
patient, affected by chronic subdural hematoma, after more 
than three months while non-sedated. In all four acute TBI 
patients, the Glasgow Coma Scale (GCS) score at admission 
was 12 or lower, while in the other patient it was 15. All 
TBI patients had a CT scan with signs of brain trauma. 
Three TBI patients had an ICP monitor at the time of 
observation, two of them had an ICP lower than 20 mmHg 
and one patient had an ICP of 25 mmHg; one TBI patient 
passed away from the severity of injuries incurred acutely.
Non-TBI patients had GCS scores between 14 and 15 
at admission; no signs of traumatic brain injury (TBI) were 
reported on the CT scan; non-TBI patients were all awake 
and orientated at the time of recording.
Two TBI and three non-TBI patients were scanned with 
the NIRO-200NX; three TBI and two non-TBI patients 
with the ISS-OxiplexTSTM.
Initially, the data were acquired from 15 moderate and 
severe TBI (12 males; mean age: 30) and 12 non-TBI 
patients (8 males; mean age: 48). However, the analysis 
had to be reduced to the aforementioned five moderate or 
severe TBI and five non-TBI patients because of the low 
signal-to-noise ratio in the rest of the sample.
Data acquisition
The study [Near Infra RED Cerebral Spectroscopy in the 
DIrection And early MONitoring of therapy in patients 
with traumatic brain injury (RED DIAMOND)] was 
approved by the East of England-Cambridge Central 
Research Ethics Board (Ref REC: 14/EE/0165; IRAS 
ID: 144979). Awake patients took part in this study after 
providing informed written consent. For those in an 
incapacitated state, a written consent form was received 
from the next of kin or from a person designated to give 
consent. The study conforms to the Declaration of Helsinki 
(as revised in 2013).
The optical probes were positioned on the patients’ 
foreheads to monitor each hemisphere (Figure 1). The 
channels’ positions were consistent across participants. If 
the signal was oversaturated, a bandage or a black sheet was 
applied on top of the probes to reduce ambient light. Awake 
participants were instructed to stay as still as they could.
An ICG powder for injection of 25 mg, Verdye 
Figure 1 Representation of the positions of the NIRO-200NX 
probes on a TBI patient’s forehead in ITU. A scale shows the 
distance in centimeters between one of the two probes and the 
patient’s nasion. TBI, traumatic brain injury; ITU, intensive 
therapy unit.
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Figure 2 Examples of changes to the EAC evaluated with the (A) FD-NIRS ISS-OxiplexTSTM and the (B) CW-NIRS, NIRO-200NX. 
EAC, effective attenuation coefficient.
(Diagnostic Green GmbH, Aschheim, Germany), was 
mixed with 25 mL of water for injection. From this solution, 
two boluses of 5 mL of 1 mg/mL ICG were injected into 
the patients’ venous peripheral cannulae or central lines. 
Following each injection, 5 mL of saline for injection was 
immediately flushed into the same cannula.
The optical signal was recorded for 2 and 10 minutes, 
respectively, before and after each ICG injection.
NIRS data analysis
ICG’s kinetic
The ICG passage through the brain was assessed by 
evaluating the changes to EAC based on the CW light 
attenuation with distance (Figure 2) (27).
The phase shift registered by the FD-NIRS ISS-
OxiplexTSTM was ignored.
The EAC (expressed in mm−1) is proportional to the 
geometric mean of the absorption and reduced scattering 
coefficients of the volume investigated (33). Since the 
reduced scattering coefficient can be considered constant 
during the ICG dynamic, changes to EAC were considered 
directly related to the effect of the ICG absorption.
The EAC measured by the CW-NIRS and the FD-NIRS 
devices were combined: given their similar wavelengths, the 
changes to EAC at the wavelengths 735 and 690 nm (red) 
and the changes at 810 and 830 nm (infrared) were merged 
together.
In order to compare the EAC temporal dynamics 
among different subjects, the EAC curves were normalized 
(z-scored), and several parameters were evaluated. A first 
parameter to be evaluated was the width of the EAC curve. 
This width was estimated at 30% of the maximum EAC 
value (expressed in s, Figure 3A). Moreover, the EAC 
temporal dynamic was divided into three temporal ranges 
characterized by an early exponential increase, an early 
exponential decay, and a late linear decay (Figure 3B,C,D). 
The parameters associated with these three temporal 
ranges were two exponential rates of increase (positive 
value) and decay (negative value) and one rate of linear 
decay (negative value), all expressed in s−1. The late liner 
decay was considered for up to 5 minutes from injection 
due to the low ICG signal-to-noise ratio beyond this. The 
four extracted curve parameters were separately compared 
between the TBI and non-TBI groups using Student’s t-test.
Similar to other contrast-enhanced imaging techniques 
(e.g., CT, MRI), the early exponential decay, the late linear 
decay and the width of the first passage of the dye bolus are 
indicative of cerebral perfusion; the early exponential decay 
was related to the ICG washing out which can be delayed 
if the ICG passed from the vascular space, where it was 
physiologically confined, to the interstitial brain tissue 
following BBB damage (18,34). A translation of the ICG 
optical signal on TBI patients into absolute parameters 
of cerebral blood flow (CBF) and BBB may be inaccurate 
and unnecessary to answer the current clinical needs (14). 
As a result, the analysis of the ICG kinetic was limited to 
the differences in ICG optical signal between the TBI and 
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Figure 3 Example of a normalized (z-scored) EAC dynamic following ICG injection. Four parameters were extracted from each EAC 
curve: (A) width; (B) rate of early exponential increase; (C) rate of early exponential decay; and (D) rate of late linear decay. EAC, effective 
attenuation coefficient; ICG, indocyanine green.
ICG’s optical properties
During the late linear decay, changes in the z-score of 
EAC in the TBI and non-TBI groups were merged 
together and the late linear decay between the red and the 
infrared were compared using the paired sample t-test. 
As mentioned in Sec. ICG’s kinetic, changes of EAC 




Figure 4 shows averaged and normalized EAC temporal 
dynamics of TBI and non-TBI patients for different 
combinations of channel locations (left and right) and 
wavelengths (red and infrared).
The standard error of the mean is also reported. Clear 
differences between TBI and non-TBI ICG temporal 
dynamics are visible.
Figure 5 displays box-and-whisker plots of the various 
parameters for different combinations of channel locations 
(left and right), wavelengths (red and infrared) and groups 
(TBI and non-TBI patients).
Significant statistical differences between TBI and 
non-TBI patients (P<0.05) were obtained for the width 
parameter of the infrared signal in the right channel 
(t-score: 2.34, df=8, P=0.04) and for the early exponential 
decay parameter of the InfraRed signal in the right channel 
(t-score: 3.12, df=8, P=0.01). Although not statistically 
significant, a similar trend for the width (larger for TBI 
patients) and the rate of early exponential decay (smaller in 
absolute value for TBI patients) parameters were found for 
all combinations of channels and colors. On the contrary, 
the rate of exponential increase and rate of late linear decay 
did not show any significant differences between the two 
groups considered.
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Figure 4 Average of the normalized (z-scored) EAC curves in TBI and non-TBI patients. (A) Right channel, infrared light; (B) right 
channel, red light; (C) left channel, infrared light; and (D) left channel, red light. EAC, effective attenuation coefficient; TBI, traumatic 
brain injury.
ICG’s optical properties
In order to evaluate possible changes with time in the 
ICG optical properties, statistical comparisons (Student’s 
paired t-tests) between the EAC curve parameters at 
each wavelength were performed. Interestingly, the 
rate of late linear decay was the only parameter showing 
statistically significant differences between red and infrared 
(t-score: 2.38, df=9, P=0.04). Considering the temporal 
characteristics and the negative values of the rate of late 
linear decay, the result depicts a stronger increase in the 
attenuation in the InfraRed, probably associated with a slow 




During the first ICG passage, in the right channels for the 
InfraRed color, the width and the early exponential decay of 
the EAC curve were significantly different between TBI and 
non-TBI patients. This can be related to reduced cerebral 
perfusion in the TBI group than in the non-TBI one, which 
slows the movement of the ICG bolus through the brain in 
the former as opposed to the latter. This result agrees with 
the literature where a broader curve of bolus passage due to 
vascular impairment is reported (35).
Similar trends in the width and early exponential decay 
were also seen in the left channels, however, the difference 
between TBI and non-TBI patients was not significant. The 
cerebral perfusion in TBI patients is inhomogeneous across 
the brain, therefore the different grades of width and early 
exponential decay between right and left channels could be 
the result of different grades of abnormal perfusion between 
hemispheres after a brain injury.
In both channels, there was no significant difference in 
the initial increase between the TBI and non-TBI groups. 
Previous studies in brain trauma and stroke patients 
reported changes of diffuse reflectance due to a delayed 
dye inflow related to vascular impairments (15,35-38). 
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Figure 5 Box-and-whisker plots of the different parameters for different combinations of channel locations (left and right), wavelengths (red 
and infrared) and groups (TBI and non-TBI patients). The EAC curve parameters evaluated were (A) width; (B) rate of exponential increase; 
(C) rate of early exponential decay; and (D) rate of late linear decay. EAC, effective attenuation coefficient; TBI, traumatic brain injury.
However, there was no evidence of a similar delay in 
this study. The disagreement between the results herein 
exposed and those reported by previous studies can be 
related to the different optical analyses performed. In 
those aforementioned studies, the delay of ICG inflow was 
assessed through a comparison between intracranial (ICT) 
and extracranial tissues (ECT) or between hemispheres 
in the same patient. This was possible either because the 
vascular lesion of stroke patients could be identified in a 
specific hemisphere, or because the use of a time-domain 
(TD)-NIRS allowed for the separation of the ECT and 
ICT signals by plotting the distribution of time of flight of 
photons (DTOF). These two analyses were not possible in 
this study: in TBI patients a comparison between affected 
and non-affected hemispheres cannot easily be performed 
as the reduction of cerebral perfusion often affects different 
parts of the brain inconsistently; the optical analysis 
performed herein facilitated the relation of changes in 
optical signal according to depth, but not the separation 
of inflow into the ECT and the ICT as can be done using 
DTOF. It should be noted that, in agreement with our 
results, a direct comparison of values of initial increase 
between patients with vascular impairments and controls 
did not show a significant difference (37).
ICG’s retention
Although, in both channels, the late linear decay was not 
significantly different between TBI and non-TBI patients, 
in the right channel, the trend suggests a higher level of 
photon absorption by ICG in the TBI group than in the 
non-TBI one.
In the minutes which followed the first ICG bolus 
passage, the continuous decrease of ICG concentration 
in the illuminated volume is related to the dilution of dye 
within the blood compartment and its uptake by the liver 
(20,39). This process can be delayed in areas with BBB 
damage due to dye leakage into the interstitial tissue. In 
such a scenario, the dye outflows from the vascular system 
until its concentration in the vessels is lower than that in 
the interstitial tissue (34). These kinetics explain the higher 
concentration of the dye measured in the right channel of 
the TBI patients. The lack of statistical significance of the 
late linear decay in the right channels between the TBI and 
non-TBI groups may be related to the small sample size 
considered.
It should also be noted that the BBB damage may be 
present in some brain areas only and the ICG leakage 
would thus be limited to these areas alone (40). Therefore, 
some TBI patients may not have had BBB damage in 
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their right hemisphere and so did not show a higher 
ICG concentration, with consequences for the statistical 
difference between the groups. Similarly, the different levels 
of EAC between right and left channels may be due to the 
inhomogeneity of BBB damage across the injured brain, 
which itself may have been present in the right rather than 
the left hemisphere in the TBI population examined.
Extracranial trauma patients as controls
A comparison between trauma patients could increase the 
accuracy of the analysis of brain abnormalities through ICG 
kinetics. To our knowledge, this is the first study that has 
analyzed ICG kinetics in the brain of TBI patients using 
patients who suffered extracranial trauma as controls.
After a trauma, liver perfusion can be reduced with 
consequences for ICG clearance (41,42). Hence, a 
comparison between healthy subjects and TBI patients 
may mistake hepatic perfusion abnormalities for alterations 
in the brain, or the former can influence the values of the 
latter.
Furthermore, there can be a systemic inflammatory 
response following a trauma (43). As highlighted regarding 
liver perfusion abnormalities, a comparison between TBI 
and non-TBI patients helps to reduce the effects that an 
inflammatory response can have on the results obtained.
ICG’s optical properties
During the late linear decay, there was a significant increase 
of ICG photon absorption at the InfraRed light compared 
to that at the Red light. This is in agreement with the 
changes in ICG absorption peak following binding with 
plasma components and explains why ICG kinetics could 
have been monitored using InfraRed rather than Red 
wavelengths (19,23).
However, contrary to our hypothesis, there was no 
spectral stabilization a few seconds post-injection as the 
changes of ICG optical properties continued throughout 
the late linear decay. The longer time for ICG spectral 
stabilization to occur could be related to the need for the 
bolus to disperse into the bloodstream. This explanation is 
partially in agreement with a previous study that showed 
changes of optical density in vivo after 20–35 seconds from 
the ICG injection, due to the dye-blood intermixing process 
(44). It should also be noted that in that study, the authors 
calculated the ICG optical properties retrospectively at 
the beginning of the recording based on the spectrum of 
absorption once the dye was intermixed with blood (44).
The time of spectral stabilization may also have been 
prolonged by the formation of ICG aggregates while the ICG 
was dissolved in a water solution before it was injected. This 
is because the ICG aggregates cannot directly bind to plasma 
compounds, but they are progressively disaggregated into 
monomers by the binding process (23). The percentage of 
ICG aggregates, and so the time of spectral stabilization, would 
vary between patients because the time that the ICG stays in 
a pre-injection water solution is not constant. Furthermore, 
the different percentages of ICG aggregates between patients 
would affect the extent of any changes to ICG optical 
properties during the spectral stabilization, as ICG aggregates 
and monomers have different absorption peaks.
The small sample size considered in this study does not 
allow for an in-depth analysis of the changes in optical 
properties across individuals. However, considering the 
prolonged time for spectral stabilization to occur during 
in vivo experiments, future studies should investigate the 
variables connected to the changes of ICG absorption 
spectrum, as this may affect the accuracy of the kinetic 
analysis and measurements of the ICG concentration. 
Inaccuracies in the values of ICG concentration could be 
particularly relevant when the ICG concentration is used to 
retrieve absolute values of CBF and BBB damage (14). In 
addition, these results suggest that even if the dye kinetics 
can be mainly monitored using InfraRed wavelengths at 
approximately 810 nm, analysis at multiple wavelengths 
should be preferred during in vivo experiments in order to 
track the changes of dye optical properties.
Limitations
Signal-to-noise ratio
A low signal-to-noise ratio may completely obscure the 
initial increase and the early exponential decay and severely 
compromise the late linear decay of an EAC curve. As a 
consequence, the quality of the recording related to that 
injection would be irreversibly affected.
The initial group of 15 TBI and 12 non-TBI patients 
had to be reduced to five TBI and five controls because 
of poor signal-to-noise ratios. This can be explained by 
the difficulties in acquiring data in challenging clinical 
environments due to multiple elements (e.g., illuminated 
environment, ecchymosis on the scalp, mechanical 
constraints) or the diff iculties in clinicians using 
commercially available NIRS devices. In its current state, 
this level of quality control exclusion would not allow for 
direct translation of this technique into clinical practice.
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Merged signal from different wavelengths
The diffuse reflectance obtained at different wavelengths 
(810, 830, and 690, 735 nm, respectively) was merged 
together. This can be considered an approximation and may 
have interfered with the accuracy of the results.
Fluorescence signal
The fluorescence signal emitted by the ICG was not 
considered in this study.
Steinkellner et al. highlighted that in a system based on 
the level of dye photon absorption, its fluorescence signal 
should be considered as contamination (35). However, 
using a TD-NIRS device with and without fluorescence 
blocking filters, they reported a negligible effect of the 
fluorescence signal on the total number of photons, which 
can be considered as the optical signal measured in the 
study herein presented (35).
Sedation
Four of the TBI patients were sedated at the time of the 
measurement, while none of the controls were under 
sedation. The drugs used to sedate the TBI patients (e.g., 
propofol, midazolam) have a hypoperfusion effect on the 
CBF (7,45). The different cerebral perfusion measured 
between the two groups could be partially explained by 
the effect of these drugs in the sedated patients. It should 
be noted that the different results between right and left 
channels suggests that the reduction of cerebral perfusion 
cannot be limited to the effects of the sedation alone.
Comparison of the optical parameters measured with 
biomarkers of brain trauma
The aims of this study were limited to the differences in 
optical signal between TBI and non-TBI patients, and no 
analysis was carried out to investigate correlation between 
the optical abnormities detected and other TBI biomarkers 
(e.g. hyperglycemia) (46).
Future multimodal monitoring studies should investigate 
how optical abnormalities are linked with other TBI 
biomarkers in order to better understand the pathogenetic 
mechanism responsible for these abnormalities and to 
include the optical results in TBI biosignatures for clinical 
practice (10,47).
Conclusions
To conclude, using contrast-enhanced NIRS, we registered 
differing ICG kinetics between a TBI and a non-TBI group 
of patients. This difference can be related to abnormalities 
of cerebral perfusion and vascular permeability following 
a brain injury. Future larger studies should better quantify 
the changes in ICG kinetic after brain injury and test the 
efficacy of these values to enhance the treatments of TBI 
patients.
We also report difficulties in collecting high-quality 
optical data in clinical settings. This calls into question the 
viability of current commercially available NIRS devices for 
contrast-enhanced neuromonitoring for clinical purposes. 
Future work should aim to enhance the user-friendliness of 
these optical devices for applications of contrast-enhanced 
NIRS in clinical settings, similar to what has been done in 
other optical techniques (48,49).
Contrary to our hypothesis, changes in ICG optical 
properties were seen for minutes after injection. Future 
research should aim to better define the pattern of changes 
of ICG optical properties during in vivo experiments to 
enhance the accuracy of contrast-enhanced NIRS with 
ICG.
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